









市場
/
株式
/
nasdaq-axsm
/

Axsome Therapeutics Inc

AXSM

152.650USD

+5.650+3.84%

終値 12/19, 16:00（ET）15分遅れの株価

7.68B時価総額

損失額直近12ヶ月PER



Axsome Therapeutics Inc

152.650

+5.650+3.84%

概要企業名金融分析

概要

企業名

金融

分析

詳細情報 Axsome Therapeutics Inc 企業名

Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.

Axsome Therapeutics Incの企業情報



企業コードAXSM

会社名Axsome Therapeutics Inc

上場日Nov 19, 2015

最高経営責任者「CEO」Tabuteau (Herriot)

従業員数683

証券種類Ordinary Share

決算期末Nov 19

本社所在地One World Trade Center, 29Th Floor

都市NEW YORK

証券取引所NASDAQ OMX - NASDAQ BASIC

国United States of America

郵便番号10007

電話番号12123323241

ウェブサイトhttps://www.axsome.com/

企業コードAXSM

上場日Nov 19, 2015

最高経営責任者「CEO」Tabuteau (Herriot)

Axsome Therapeutics Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Roger A. Jeffs, Ph.D.

Independent Director

57.51K

-18.97%

Mr. Nick Pizzie, CPA

Chief Financial Officer

42.67K

-1.00%

Mr. Mark E. Saad

Independent Director

10.30K

Dr. Herriot Tabuteau, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

7.23K

Mr. Hunter Murdock

General Counsel

Mr. Mark L. Jacobson

Chief Operating Officer

-100.00%

Dr. Susan M. (Sue) Mahony, Ph.D.

Independent Director

Dr. Mark Coleman, M.D.

Lead Independent Director

Mr. Ari Maizel

Chief Commercial Officer

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Roger A. Jeffs, Ph.D.

Independent Director

57.51K

-18.97%

Mr. Nick Pizzie, CPA

Chief Financial Officer

42.67K

-1.00%

Mr. Mark E. Saad

Independent Director

10.30K

Dr. Herriot Tabuteau, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

7.23K

Mr. Hunter Murdock

General Counsel

Mr. Mark L. Jacobson

Chief Operating Officer

-100.00%

収益内訳

通貨: USD更新時刻: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2023

FY2023Q4

FY2023Q3

事業別USD

会社名

収益

比率

Auvelitv

119.64M

80.32%

Sunosi

28.91M

19.41%

Sunosi royality revenue

1.08M

0.73%

Sunosi License revenue

410.00K

0.28%

地域別USD

会社名

収益

比率

United States

146.45M

98.31%

Outside of the United States

2.51M

1.69%

事業別

地域別

事業別USD

会社名

収益

比率

Auvelitv

119.64M

80.32%

Sunosi

28.91M

19.41%

Sunosi royality revenue

1.08M

0.73%

Sunosi License revenue

410.00K

0.28%

株主

更新時刻: Sun, Nov 16

株主統計

種類

株主統計

比率

Antecip Capital, L.L.C.

14.57%

The Vanguard Group, Inc.

8.28%

BlackRock Institutional Trust Company, N.A.

6.16%

Wellington Management Company, LLP

2.65%

RTW Investments L.P.

2.22%

他の

66.13%

株主統計

比率

Antecip Capital, L.L.C.

14.57%

The Vanguard Group, Inc.

8.28%

BlackRock Institutional Trust Company, N.A.

6.16%

Wellington Management Company, LLP

2.65%

RTW Investments L.P.

2.22%

他の

66.13%

種類

株主統計

比率

Investment Advisor

36.04%

Investment Advisor/Hedge Fund

21.86%

Corporation

14.57%

Hedge Fund

11.48%

Research Firm

2.23%

Private Equity

1.35%

Individual Investor

1.13%

Pension Fund

1.11%

Sovereign Wealth Fund

0.93%

他の

9.30%

機関投資家保有株



更新時刻: Mon, Dec 8

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q4

643

38.50M

85.28%

+81.77K

2025Q3

657

38.45M

87.16%

-264.98K

2025Q2

636

38.74M

85.21%

+673.17K

2025Q1

604

38.08M

85.89%

-4.20M

2024Q4

561

37.78M

89.40%

-1.53M

2024Q3

529

39.25M

94.83%

-2.09M

2024Q2

515

41.51M

92.29%

+1.90M

2024Q1

502

39.61M

93.44%

-4.74M

2023Q4

476

39.34M

91.45%

+441.54K

2023Q3

467

38.94M

87.84%

+1.52M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

Antecip Capital, L.L.C.

7.34M

14.72%

Apr 14, 2025

The Vanguard Group, Inc.

3.94M

7.89%

+67.64K

+1.75%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.14M

6.3%

+173.97K

+5.86%

Jun 30, 2025

Wellington Management Company, LLP

725.04K

1.45%

+21.77K

+3.09%

Jun 30, 2025

RTW Investments L.P.

1.52M

3.04%

-1.41M

-48.10%

Jun 30, 2025

Nomura Investment Management Business Trust

1.14M

2.28%

+161.49K

+16.54%

Jun 30, 2025

Geode Capital Management, L.L.C.

989.45K

1.98%

+54.60K

+5.84%

Jun 30, 2025

T. Rowe Price Associates, Inc.

575.94K

1.15%

+546.97K

+1888.32%

Jun 30, 2025

Invesco Advisers, Inc.

528.53K

1.06%

-217.30K

-29.14%

Jun 30, 2025

State Street Investment Management (US)

958.50K

1.92%

+52.48K

+5.79%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

よくある質問

Axsome Therapeutics Incの上位5名の株主は誰ですか？



Axsome Therapeutics Incの上位5名の株主は以下のとおりです。
Antecip Capital, L.L.C.は7.34M株を保有しており、これは全体の14.72%に相当します。
The Vanguard Group, Inc.は3.94M株を保有しており、これは全体の7.89%に相当します。
BlackRock Institutional Trust Company, N.A.は3.14M株を保有しており、これは全体の6.30%に相当します。
Wellington Management Company, LLPは725.04K株を保有しており、これは全体の1.45%に相当します。
RTW Investments L.P.は1.52M株を保有しており、これは全体の3.04%に相当します。